Overview

The goal of this study is to evaluate the lung-cleansing effects of L Max by measuring changes in Participant Reported Outcome (PRO) Scores and athletic performance. Researchers will compare the results of participants who take L Max and participants who take placebo (a look-alike substance that contains no active ingredient).

Participants will:

1. Wear an Oura Ring continuously throughout the study
2. Perform spirometry (a measurement of your lung health) daily
3. Fill out short daily exercise and health logs
4. Perform three timed athletic performance tests over the course of the study and record the results
5. Fill out Participant Reported Outcomes Surveys three times over the course of the study
6. Fill out study product surveys twice over the course of the study
7. Participate in an optional exit survey at the end of the study

Eligibility

Inclusion Criteria:

1. Aged 18 to 60 years
2. US-based
3. Committed endurance athlete with cycling, triathlon or running focus
4. Achieves three or more Zone 3+ sessions/week
5. Tracks power and time during training
6. Able to use Oura, spirometry, and training apps
7. Routinely feels pulmonary system/breathing limits athletic performance
8. If diagnosed with exercise induce asthma, able to use inhaler only as rescue and not preventatively.
9. Women of childbearing potential (WOCBP) must agree to use highly effective contraception starting at least 14 days prior to the first dose of L Max or placebo, throughout the study period, and for at least 30 days after the last dose of study product.

   Highly effective methods include the following: abstinence, oral contraceptives, contraceptive injections, intrauterine device, double barrier method (Diaphragm or condom + spermicidal cream) contraceptive patch, or male partner sterilization. Women who are postmenopausal (at least 12 months of spontaneous amenorrhea without an alternative medical cause) or surgically sterile (e.g. hysterectomy, salpingectomy, bilateral oophorectomy, or bilateral tubal ligation) are not considered of childbearing potential.

10. Willing to practice a reliable method of contraception for the duration of the study
11. In good general health at the time of screening (Investigator discretion).
12. Able to read and understand English
13. Able to read, understand, and provide informed consent
14. Able to use a personal smartphone device and download Chloe by PeopleScience, Oura, and MIR Spirobank
15. Able to receive shipment of the product at an address within the United States
16. Able to complete study assessments over the course of up to 6 weeks.

Exclusion Criteria:

1. Do not have a personal smartphone, internet access, or are unwilling to download Chloe, Oura, or MIR Spirobank apps
2. Daily/preventative inhaler use
3. Injury, illness, or poor training compliance in the previous 6 months
4. History of COPD, long COVID, fibromyalgia, chronic fatigue syndrome, Lyme disease, or major cardiac or respiratory conditions
5. Lack of access to indoor trainer with power meter
6. High alcohol use or ongoing recreational drug/tobacco use
7. Pregnant, planning to become pregnant during the study, or lactating
8. Use of medications to treat hypertension (high blood pressure) including diuretics, Angiotensin Converting Enzyme inhibitors, Angiotensin II Receptor Blockers, calcium channel blockers, beta blockers, alpha blockers, and other classes used for blood pressure control
9. Any underlying medical conditions or comorbidities that may confound the assessment or the evaluation of the study outcomes.
10. Have a significant illness, disease, or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes.
11. Known hypersensitivity or previous allergic reaction to sodium bicarbonate, citrate, theobromine, arginine, forskolin, maltodextrin, modified food starch, or lactose
12. Are unlikely for any reason to be able to comply with the trial or are considered unsuited for participation in the study by the Principal Investigator.